Cargando…
Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium
Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/11...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391859/ https://www.ncbi.nlm.nih.gov/pubmed/37528464 http://dx.doi.org/10.1186/s40164-023-00430-1 |
_version_ | 1785082814343938048 |
---|---|
author | Jiang, Yuanhong Wu, Siyu Li, Rong Yu, Jiazheng Zheng, Jianyi Li, Zeyu Li, Mingyang Xin, Kerong Xu, Zhenqun Li, Shijie Chen, Xiaonan |
author_facet | Jiang, Yuanhong Wu, Siyu Li, Rong Yu, Jiazheng Zheng, Jianyi Li, Zeyu Li, Mingyang Xin, Kerong Xu, Zhenqun Li, Shijie Chen, Xiaonan |
author_sort | Jiang, Yuanhong |
collection | PubMed |
description | Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC. Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280. We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials. |
format | Online Article Text |
id | pubmed-10391859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-103918592023-08-02 Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium Jiang, Yuanhong Wu, Siyu Li, Rong Yu, Jiazheng Zheng, Jianyi Li, Zeyu Li, Mingyang Xin, Kerong Xu, Zhenqun Li, Shijie Chen, Xiaonan Exp Hematol Oncol Correspondence Numerous novel and effective therapeutic agents and clinical trials addressing castration-resistant prostate cancer (CRPC) were reported during the 2023 American Society of Clinical Oncology-Genitourinary (ASCO-GU) Cancers Symposium. Notably, radionuclide drug conjugates (RDC), specifically 177Lu/111In-J591 and 225Ac-J591, exhibited enhanced therapeutic efficacy in treating patients with CRPC. Furthermore, promising treatment approaches for CRPC included dual anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed death-1 (PD-1) blockade in rare tumors (DART)-Lorigerlimab, prostate stem cell antigen (PSCA)-directed chimeric antigen receptor (CAR)-T cell immunotherapy-BPX-601, and protein kinase inhibitor (AKTi)-CAPltello-280. We have summarized the latest CRPC treatment strategies presented at the 2023 ASCO-GU Cancers Symposium, along with recent advances in CRPC clinical trials. BioMed Central 2023-08-01 /pmc/articles/PMC10391859/ /pubmed/37528464 http://dx.doi.org/10.1186/s40164-023-00430-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Correspondence Jiang, Yuanhong Wu, Siyu Li, Rong Yu, Jiazheng Zheng, Jianyi Li, Zeyu Li, Mingyang Xin, Kerong Xu, Zhenqun Li, Shijie Chen, Xiaonan Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium |
title | Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium |
title_full | Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium |
title_fullStr | Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium |
title_full_unstemmed | Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium |
title_short | Novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 ASCO-GU Cancers Symposium |
title_sort | novel agents and clinical trials in castration-resistant prostate cancer: latest updates from 2023 asco-gu cancers symposium |
topic | Correspondence |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391859/ https://www.ncbi.nlm.nih.gov/pubmed/37528464 http://dx.doi.org/10.1186/s40164-023-00430-1 |
work_keys_str_mv | AT jiangyuanhong novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT wusiyu novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT lirong novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT yujiazheng novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT zhengjianyi novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT lizeyu novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT limingyang novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT xinkerong novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT xuzhenqun novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT lishijie novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium AT chenxiaonan novelagentsandclinicaltrialsincastrationresistantprostatecancerlatestupdatesfrom2023ascogucancerssymposium |